Document is current
Any future updates will be listed below
-
Authors
Kaufmann, Tom L. https://orcid.org/0000-0003-4374-1338
Petkovic, Marina https://orcid.org/0000-0003-2875-216X
Watkins, Thomas B. K. https://orcid.org/0000-0001-7414-737X
Colliver, Emma C. https://orcid.org/0000-0002-1497-0740
Laskina, Sofya
Thapa, Nisha
Minussi, Darlan C. https://orcid.org/0000-0001-8856-4625
Navin, Nicholas https://orcid.org/0000-0002-2106-8624
Swanton, Charles https://orcid.org/0000-0002-4299-3018
Van Loo, Peter https://orcid.org/0000-0003-0292-1949
Haase, Kerstin https://orcid.org/0000-0002-0944-5618
Tarabichi, Maxime https://orcid.org/0000-0002-1635-2348
Schwarz, Roland F. https://orcid.org/0000-0001-9155-4268
- License Information
-
More Information
Article History
Received: 15 November 2021
Accepted: 12 October 2022
First Online: 14 November 2022
Change Date: 11 February 2023
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: Not applicable.
: Not applicable.
: C.S. acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Archer Dx Inc. (collaboration in minimal residual disease sequencing technologies), and Ono Pharmaceutical; is an AstraZeneca Advisory Board Member and Chief Investigator for the MeRmaiD1 clinical trial; has consulted for Amgen, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, AstraZeneca, Illumina, Genentech, Roche Ventana, GRAIL, Medicxi, Bicycle Therapeutics, Metabomed and the Sarah Cannon Research Institute; has stock options in Apogen Biotechnologies, Epic Bioscience, and GRAIL; and has stock options and is co-founder of Achilles Therapeutics. C.S. holds patents relating to assay technology to detect tumor recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), to treating cancer by targeting Insertion/deletion mutations (PCT/GB2018/051893), identifying insertion/deletion mutation targets (PCT/GB2018/051892); methods for lung cancer detection (PCT/US2017/028013), identifying responders to cancer treatment (PCT/GB2018/051912); and a patent application to determine methods and systems for tumor monitoring (GB2114434.0).
